Latest Breaking News On - Service line program - Page 1 : comparemela.com

email article Treatment with an HIV maturation inhibitor known as GSK3640254 or the catchy name of GSK 254 for short appeared to dramatically lower viral load in a proof-of-concept phase IIa clinical trial, researchers reported. In a 7-day trial that tested multiple doses of GSK 254, viral loads were reduced by a factor of 50 with a dose of 140 mg and by a factor of 100 with a 200-mg dose, according to Christoph Spinner, MD, of Technical University of Munich, who presented the findings at the virtual Conference on Retroviruses and Opportunistic Infections (CROI). Phase III trials will test GSK 254 at doses of 100, 150, and 200 mg in once-daily dosing, Spinner said, in combination with two nucleoside reverse transcriptase inhibitors in treatment-naïve individuals.

New yorkUnited statesJosephp mcgowanTechnical university of munichNorthwell healthService line programChristoph spinnerTechnical universityOpportunistic infectionsOnline programMedpage todayHuman immunodeficiency virus infectionImmunodeficiency disorderபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்தொழில்நுட்ப பல்கலைக்கழகம் ஆஃப் முனிச்